Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease
Tuberculosis (TB) drug discovery and development has undergone nothing short of a
revolution over the past 20 years. Successful public–private partnerships and sustained …
revolution over the past 20 years. Successful public–private partnerships and sustained …
Exploiting cAMP signaling in Mycobacterium tuberculosis for drug discovery
D Kathayat, BC VanderVen - Trends in Microbiology, 2024 - cell.com
Mycobacterium tuberculosis (Mtb) replicates within host macrophages by adapting to the
stressful and nutritionally constrained environments in these cells. Exploiting these …
stressful and nutritionally constrained environments in these cells. Exploiting these …
[HTML][HTML] A mathematical analysis of the two-strain tuberculosis model dynamics with exogenous re-infection
The rise of drug resistance has become a major obstacle in treating tuberculosis (TB),
significantly contributing to the increasing disease burden. Therefore, it is essential to study …
significantly contributing to the increasing disease burden. Therefore, it is essential to study …
Why do we use 100 mg of clofazimine in TB and NTM treatment?
J van Ingen - Journal of Antimicrobial Chemotherapy, 2024 - academic.oup.com
Current tuberculosis and non-tuberculous mycobacterial disease guidelines recommend the
use of clofazimine in a 100 mg once-daily dose. The rationale behind this exact dose is not …
use of clofazimine in a 100 mg once-daily dose. The rationale behind this exact dose is not …
[HTML][HTML] Treatment outcomes and risk factors for an unsuccessful outcome among patients with highly drug-resistant tuberculosis in Ukraine
OS Pedersen, T Butova, V Kapustnyk… - Clinical Microbiology …, 2024 - Elsevier
Objectives To describe demographics, clinical features, and treatment outcomes of patients
with highly drug-resistant tuberculosis (TB) in Ukraine, and to evaluate risk factors for an …
with highly drug-resistant tuberculosis (TB) in Ukraine, and to evaluate risk factors for an …
Dual Inhibition of Mycobacterium tuberculosis and the Host TGFBR1 by an Anilinoquinazoline
M Nandakumar, A Ollodart, N Fleck… - Journal of Medicinal …, 2023 - ACS Publications
Tuberculosis (TB) control is complicated by the emergence of drug resistance. Promising
strategies to prevent drug resistance are the targeting of nonreplicating, drug-tolerant …
strategies to prevent drug resistance are the targeting of nonreplicating, drug-tolerant …
Metabolites from Streptomyces aureus (VTCC43181) and Their Inhibition of Mycobacterium tuberculosis ClpC1 Protein
TTP Tran, NNT Huynh, NT Pham, DT Nguyen, CV Tran… - Molecules, 2024 - mdpi.com
Tuberculosis is one of the most common infectious diseases in the world, caused by
Mycobacterium tuberculosis. The outbreak of multiple drug-resistant tuberculosis has …
Mycobacterium tuberculosis. The outbreak of multiple drug-resistant tuberculosis has …
Multidrug-resistant tuberculosis
K Dheda, F Mirzayev, DM Cirillo, Z Udwadia… - Nature Reviews …, 2024 - nature.com
Tuberculosis (TB) remains the foremost cause of death by an infectious disease globally.
Multidrug-resistant or rifampicin-resistant TB (MDR/RR-TB; resistance to rifampicin and …
Multidrug-resistant or rifampicin-resistant TB (MDR/RR-TB; resistance to rifampicin and …
Study protocol for safety and efficacy of all-oral shortened regimens for multidrug-resistant tuberculosis: a multicenter randomized withdrawal trial and a single-arm …
L Fu, J Xiong, H Wang, P Zhang, Q Yang, Y Cai… - BMC Infectious …, 2023 - Springer
Introduction The urgent need for new treatments for multidrug-resistant tuberculosis (MDR-
TB) and pre-extensively drug-resistant tuberculosis (pre-XDR-TB) is evident. However, the …
TB) and pre-extensively drug-resistant tuberculosis (pre-XDR-TB) is evident. However, the …
Drug-induced liver injury due to first-line antituberculosis medications in India: A major hindrance to achieve the goal of tuberculosis elimination
H Gopalakrishna, N Chalasani - Indian Journal of Gastroenterology, 2024 - Springer
Tuberculosis (TB), caused by Mycobacterium tuberculosis, remains a major global health
and economic burden, ranking among the leading infectious disease causes for mortality [1] …
and economic burden, ranking among the leading infectious disease causes for mortality [1] …